videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

Idogen

Meet Idogens CEO Anders Karlsson the 5th. of May 2022. Topics for the event: Presentation of Q1 report Swedish and Norwegian approval for its clinical phase 1/2a study with IDO 8, a completely...

Meet Idogens CEO Anders Karlsson the 5th. of May 2022.
Topics for the event:

<ul style="font-weight: 400;">
 	<li>Presentation of Q1 report</li>
 	<li>Swedish and Norwegian approval for its clinical phase 1/2a study with IDO 8, a completely new type of cell therapy for patients with severe hemophilia A who have developed antibodies to their treatment with coagulation factor VIII.</li>
 	<li>What should proceed from latest rights issue be used for?</li>
</ul>
Idogen develops tolerogenic cell therapies where the goal is to prevent an unwanted activation of the immune system. For patients with hemophilia A, one third of patients develop neutralizing antibodies to the standard treatment and render it inactive. To prevent the body's immune system from attacking such biological drugs, Idogen has developed a patient-specific cell therapy with the intention of creating tolerance for the patient's treatment. The goal is that the patient can thus continue with his vital treatment.
Idogen is listed on NasdaQ First North Growth Market with ticker IDOGEN.
Disclaimer: HC Andersen Capital receives payment from Idogen for a Digital IR/Corporate Visibility subscription agreement.

HC Andersen Capital

Idogen – Q1 report and update on latest development in the company - 05.05.2022

AKTIER MED FRIIS - UGE 49 2025

GreenMobility

FLSmidth & Co.

Rockwool

Boozt

HCA Morgenbørs 05/12 - Overvejende positive futures-markeder hvor kun Japan er i minus

GreenMobility: What is the investment case in driverless cars

UPM-Kymmene

UPM and Sappi are planning a joint venture in graphic papers

GreenMobility: How far away are driverless cars in Denmark

Seneste videoer